Company News-Bio-Thera Solutions, Ltd.

The European Commission (EC) Approves Bio-Thera Solutions’ BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

01-142025

Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders

Guangzhou, China – Bio-Thera Solutions, Ltd. today announced thepublication of the Phase Iclinical study results for BAT...
12-242024

Bio-Thera Solutions Partners with Tabuk Pharmaceuticals to Commercialize BAT2206, a Stelara® (Ustekinumab) Biosimilar in Saudi Arabia

Guangzhou, China, December 24, 2024 - Bio-TheraSolutions Inc.(688177:SH),a commercial-stage biopharmaceutical company de...
12-162024

Bio-Thera Solutions Expands Partnership with SteinCares in LATAM with Addition of a Third Biosimilar to Partnership

GUANGZHOU, China - Bio-Thera Solutions, a commercial-stage biopharmaceutical companydeveloping innovative therapies and ...

上一页 ···5 6 7 8 9 ··· 下一页